{
    "medicine_id": "781ccb350557e81af334aaeb31b498e2d1b3edf5",
    "platform_id": "DB04867",
    "metadata": {
        "name": "Synribo 3 5 mg 1mL Injection powder lyophilized for solution",
        "composition": "3 5 mg 1mL Lintitript",
        "clinical_particulars": {
            "therapeutic_indications": "For the treatment of pancreatic cancer and appetite disorders",
            "contraindications": {
                "disease": "NA",
                "pregnancy": "NA",
                "machine_ops": "NA",
                "pharmacodynamics": "Lintitript SR 27897 is a selective cholecystokinin type A CCK A receptor antagonist In February 2000 Sanofi announced that it was halting development of the drug for appetite disorders and in September 2002 Sanofi announced that it had stopped investigation all together",
                "excipients": "NA",
                "incompatibilities": []
            }
        },
        "revision_date": "2023-05-14"
    }
}